Yuta Ishikawa1, Richard D Lewis2, Emma M Laing3, Alex K Anderson4, Donglan Zhang5, Arshed A Quyyumi6, Sandra B Dunbar7, Rupal Trivedi-Kapoor8, Elisabeth L P Sattler9. 1. Department of Nutritional Sciences, College of Family and Consumer Sciences, University of Georgia. 305 Sanford Drive, Dawson Hall, Athens, GA 30605, USA. Electronic address: yishik@uga.edu. 2. Department of Nutritional Sciences, College of Family and Consumer Sciences, University of Georgia. 305 Sanford Drive, Dawson Hall, Athens, GA 30605, USA. Electronic address: rdlewis@uga.edu. 3. Department of Nutritional Sciences, College of Family and Consumer Sciences, University of Georgia. 305 Sanford Drive, Dawson Hall, Athens, GA 30605, USA. Electronic address: emonk@uga.edu. 4. Department of Nutritional Sciences, College of Family and Consumer Sciences, University of Georgia. 305 Sanford Drive, Dawson Hall, Athens, GA 30605, USA. Electronic address: fianko@uga.edu. 5. Department of Health Policy and Management, College of Public Health, University of Georgia. 100 Foster Road, Wright Hall, Athens, GA 30606, USA. Electronic address: dzhang@uga.edu. 6. Emory Clinical Cardiovascular Research Institute, Emory University. 1462 Clifton Road N.E. Suite 507, Atlanta, GA 30322, USA. Electronic address: aquyyum@emory.edu. 7. Department of Academic Advancement, Nell Hodgson Woodruff School of Nursing, Emory University. 1520 Clifton Road NE, Atlanta, GA 30322, USA. Electronic address: sbdunba@emory.edu. 8. Department of Clinical and Administrative Pharmacy, College of Pharmacy, University of Georgia. 250 West Green Street, R.C. Wilson Pharmacy, Athens, GA 30602, USA. Electronic address: rupal.trivedi@uga.edu. 9. Department of Nutritional Sciences, College of Family and Consumer Sciences, University of Georgia. 305 Sanford Drive, Dawson Hall, Athens, GA 30605, USA; Department of Clinical and Administrative Pharmacy, College of Pharmacy, University of Georgia. 250 West Green Street, R.C. Wilson Pharmacy, Athens, GA 30602, USA. Electronic address: lilian@uga.edu.
Abstract
AIMS: This study estimated national prevalence and trends of diagnosed and undiagnosed type 2 diabetes mellitus (T2DM) and prediabetes among heart failure (HF) patients in the U.S. METHODS: This cross-sectional study included 527 participants aged 20+ years with a diagnosis of HF, using data from the National Health and Nutrition Examination Survey 2005-2016. We assessed prevalence estimates of diagnosed and undiagnosed T2DM and prediabetes stratified by age-standardized sociodemographic and health characteristics. Trends of T2DM and prediabetes prevalence were examined using logistic regressions. RESULTS: Prevalence rates of diagnosed and undiagnosed T2DM among HF patients were 34.7% (95% confidence interval (CI), 29.2-40.3%) and 12.8% (95% CI, 9.2-16.9%), respectively. Prediabetes affected 39.1% (95% CI, 33.6-44.9%) of HF patients. Prevalence estimates of diagnosed T2DM were significantly different between non-Hispanic White (20.1% [95% CI, 13.5-27.6%]) and Hispanic participants (52.1% [95% CI, 35.9-68.0%]) (P < 0.001). The prevalence of T2DM and prediabetes did not significantly change between 2005 and 2016. CONCLUSIONS: Prevalence rates of T2DM and prediabetes among community-dwelling HF patients in the U.S. remained high between 2005 and 2016. Prevention of and targeted intervention for T2DM among at-risk HF patients is needed, particularly among those of Hispanic origin.
AIMS: This study estimated national prevalence and trends of diagnosed and undiagnosed type 2 diabetes mellitus (T2DM) and prediabetes among heart failure (HF) patients in the U.S. METHODS: This cross-sectional study included 527 participants aged 20+ years with a diagnosis of HF, using data from the National Health and Nutrition Examination Survey 2005-2016. We assessed prevalence estimates of diagnosed and undiagnosed T2DM and prediabetes stratified by age-standardized sociodemographic and health characteristics. Trends of T2DM and prediabetes prevalence were examined using logistic regressions. RESULTS: Prevalence rates of diagnosed and undiagnosed T2DM among HF patients were 34.7% (95% confidence interval (CI), 29.2-40.3%) and 12.8% (95% CI, 9.2-16.9%), respectively. Prediabetes affected 39.1% (95% CI, 33.6-44.9%) of HF patients. Prevalence estimates of diagnosed T2DM were significantly different between non-Hispanic White (20.1% [95% CI, 13.5-27.6%]) and Hispanic participants (52.1% [95% CI, 35.9-68.0%]) (P < 0.001). The prevalence of T2DM and prediabetes did not significantly change between 2005 and 2016. CONCLUSIONS: Prevalence rates of T2DM and prediabetes among community-dwelling HF patients in the U.S. remained high between 2005 and 2016. Prevention of and targeted intervention for T2DM among at-risk HF patients is needed, particularly among those of Hispanic origin.